[go: up one dir, main page]

PL2599487T3 - Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu - Google Patents

Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu

Info

Publication number
PL2599487T3
PL2599487T3 PL11812616T PL11812616T PL2599487T3 PL 2599487 T3 PL2599487 T3 PL 2599487T3 PL 11812616 T PL11812616 T PL 11812616T PL 11812616 T PL11812616 T PL 11812616T PL 2599487 T3 PL2599487 T3 PL 2599487T3
Authority
PL
Poland
Prior art keywords
agent
neuropathic pain
prophylactic
therapeutic agent
therapeutic
Prior art date
Application number
PL11812616T
Other languages
English (en)
Inventor
Naoki Izumimoto
Hidenori Mochizuki
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PL2599487T3 publication Critical patent/PL2599487T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11812616T 2010-07-30 2011-07-29 Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu PL2599487T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010171384 2010-07-30
EP20110812616 EP2599487B1 (en) 2010-07-30 2011-07-29 Therapeutic agent or prophylactic agent for neuropathic pain
PCT/JP2011/067431 WO2012015027A1 (ja) 2010-07-30 2011-07-29 神経障害性疼痛の治療剤又は予防剤

Publications (1)

Publication Number Publication Date
PL2599487T3 true PL2599487T3 (pl) 2015-09-30

Family

ID=45530226

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11812616T PL2599487T3 (pl) 2010-07-30 2011-07-29 Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu

Country Status (13)

Country Link
US (2) US8946267B2 (pl)
EP (1) EP2599487B1 (pl)
JP (1) JP5786714B2 (pl)
KR (1) KR101786818B1 (pl)
CN (1) CN103002893B (pl)
AU (1) AU2011283462B9 (pl)
BR (1) BR112013000164B1 (pl)
CA (1) CA2805371C (pl)
ES (1) ES2536534T3 (pl)
MX (1) MX2013000946A (pl)
PL (1) PL2599487T3 (pl)
RU (1) RU2544552C2 (pl)
WO (1) WO2012015027A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
EP3100726A4 (en) 2014-01-29 2017-06-14 Toray Industries, Inc. Therapeutic or prophylactic agent for multiple sclerosis
WO2018181859A1 (ja) * 2017-03-31 2018-10-04 東レ株式会社 抗がん剤誘発末梢神経障害の治療剤又は予防剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
AU677008B2 (en) 1992-05-20 1997-04-10 Northwestern University Gaba and L-glutamic acid analogs for antiseizure treatment
DK1011658T3 (da) * 1997-09-08 2006-04-03 Warner Lambert Co Analgesiske præparater, der omfatter antiepileptiske forbindelser, og fremgangsmåder til anvendelse af samme
DE69821132T2 (de) 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
KR100758609B1 (ko) 1999-08-20 2007-09-13 오르토-맥네일 파마슈티칼, 인코퍼레이티드 트라마돌 화합물 및 항경련 약물을 포함하는 조성물
AP2002002501A0 (en) 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
DK1404324T4 (da) 2001-06-11 2011-07-11 Xenoport Inc Prolægemidler af GABA analoger, sammensætninger og anvendelser deraf
GB0219024D0 (en) 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
JP2005060311A (ja) * 2003-08-13 2005-03-10 Mochida Pharmaceut Co Ltd Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
WO2005025675A1 (en) 2003-09-12 2005-03-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
WO2005035523A1 (en) 2003-10-08 2005-04-21 Pfizer Japan Inc. Fused lactam compounds
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
EP1820502A1 (en) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
US20080153874A1 (en) 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
WO2008079727A2 (en) 2006-12-22 2008-07-03 Allergan, Inc. Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
WO2009021058A2 (en) 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
KR101851120B1 (ko) 2008-09-05 2018-04-23 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
AU2011237072B2 (en) 2010-03-31 2014-09-04 Toray Industries, Inc. Therapeutic agent or prophylactic agent for fibromyalgia

Also Published As

Publication number Publication date
US20130131120A1 (en) 2013-05-23
EP2599487A1 (en) 2013-06-05
CA2805371C (en) 2017-10-31
KR101786818B1 (ko) 2017-10-18
AU2011283462B2 (en) 2014-05-22
CN103002893B (zh) 2017-05-10
AU2011283462A1 (en) 2013-02-28
JPWO2012015027A1 (ja) 2013-09-12
CA2805371A1 (en) 2012-02-02
KR20130103342A (ko) 2013-09-23
JP5786714B2 (ja) 2015-09-30
AU2011283462B9 (en) 2014-09-18
EP2599487B1 (en) 2015-04-01
US8946267B2 (en) 2015-02-03
CN103002893A (zh) 2013-03-27
BR112013000164B1 (pt) 2021-11-23
EP2599487A4 (en) 2013-12-25
ES2536534T3 (es) 2015-05-26
BR112013000164A2 (pt) 2016-05-24
RU2544552C2 (ru) 2015-03-20
US9226924B2 (en) 2016-01-05
US20150105430A1 (en) 2015-04-16
WO2012015027A1 (ja) 2012-02-02
MX2013000946A (es) 2013-02-27
RU2013108755A (ru) 2014-09-10

Similar Documents

Publication Publication Date Title
SG10201506840QA (en) Cytotoxicity-inducing therapeutic agent
PL2652193T3 (pl) Obróbka
IL222481A0 (en) Combination therapy
EP2552323A4 (en) COMBINATION THERAPY
PL2621569T3 (pl) Urządzenie lecznicze
ZA201208413B (en) Skin treatment composition
EP2521569A4 (en) COMBINATION THERAPY WITH VB-201
EP2621498A4 (en) COMBINED TREATMENT OF DERMATOLOGICAL CONDITIONS
PL2529739T3 (pl) Środek terapeutyczny lub profilaktyczny na choroby dróg żółciowych
PL2554541T3 (pl) Środek terapeutyczny lub środek profilaktyczny na fibromialgię
IL245995A0 (en) Prophylactic or medical agent for fibrosis
ZA201301458B (en) Therapeutic agent for pain
EP2560677A4 (en) COLD TREATMENT
ZA201208568B (en) Skin treatment composition
GB201013573D0 (en) Treatment
PL2599487T3 (pl) Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu
EP2595594A4 (en) MASSAGER
SI2531124T1 (sl) Naprava za zdravljenje kožnih lezij
GB201005394D0 (en) Therapy
EP2545858A4 (en) SURGICAL SPARKER
GB201014097D0 (en) Treatment
EP2629766A4 (en) COMBINATION THERAPY
PL2456445T3 (pl) Środek do leczenia chorób skóry
GB201003727D0 (en) Therapeutic agent
GB201021319D0 (en) Treatment